Online Inquiry
DNMT1 (Δexons3-5/Δexons3-5); DNMT3B (-/-); CDKN2A (sil/-) Cell Line
SPL-00920
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| DNMT1 (Δexons3-5/Δexons3-5); DNMT3B (-/-); CDKN2A (sil/-) |
| Target Information | |
|---|---|
| Target Name | p16 INK4A |
| Gene Abbr. | CDKN2A |
| Gene ID | 1029 |
| Full Name | cyclin dependent kinase inhibitor 2A |
| Alias | ARF, CDK4I, CDKN2, CMM2, INK4 |
| Species | Human |
| Genomic Locus | 19p13.2;20q11.2;9p21 |
| Introduction | This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]. |
| Product Details | |
|---|---|
| Cell Line Model | HCT116 |
| Genotype | DNMT1 (Δexons3-5/Δexons3-5); DNMT3B (-/-); CDKN2A (sil/-) |
| Description | DNMT1 (Δexons3-5/Δexons3-5); DNMT3B (-/-); CDKN2A (sil/-) |
| Parental ATCC ID | CCL-247 |
| STR Profile | Amelogenin: X,Y; CSF1PO: 7,10; D13S317: 10,12; D16S539: 11,13; D5S818: 10,11; D7S820: 11,12; THO1: 8,9; TPOX: 8,9; vWA: 17,22; ATCC |
| Disease | Colorectal carcinoma |
| Tissue | Colon |
| Gender | Male |
| Key Endogenous Mutations | CDKN2A, CTNNB1, KRAS, PIK3CA, MLH1 |
| CVT Selection Condition | G418 resistant - 0.4 mg/mL; Hygromycin resistant - 0.05 mg/mL |
| Cell Number | 2x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:10-1:20. |
| Culture Medium | RPMI 1640 including 2 mM L-glutamine and 25 mM sodium bicarbonate, supplemented with 10% FBS. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:10-1:20. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.